Skip to main content

Table 1 Changes in blood serum chemistry after the treatment with IL13-PE38QQR

From: Improved Anti-tumor Activity and Safety of Interleukin-13 Receptor Targeted Cytotoxin by Systemic Continuous Administration in Head and Neck Cancer Xenograft Model

Profile Reference Range (Units) Intravenous Administration Continuous Infusion
Control* 150 µ g/kg Control 200 µ g/kg 300 µ g/kg
Sodium 150–162 (mEq/l) 150 141 151 152 144
Potassium 3.8–6.8 (mEq/l) 6.0 20.1 5.7 5.8 16.3
CPK+ 0–800 (U/l) 179 14414 60 471 6665
LDH 260–680 (U/l) 1083 5032 663 1353 2490
AST (GOT) 72–288 (U/l) 208 1482 70 125 565
ALT (GPT) 24–140 (U/l) 76 723 28 88 91
Albumin 2.6–4.6 (g/dl) 2.8 1.9 2.5 2.7 3.4
  1. * Data represent the mean of blood samples from two animals from each group.
  2. † CPK, creatinine phosphokinase.